Sarah Meibusch

Sarah Meibusch has over twelve years of work experience in various roles. In 2009, they began their career as a Principal at BearTrap Solutions Pty Ltd, a consulting company. In 2012, they joined Queensland Alliance for Agriculture and Food Innovation (QAAFI) as a Member of the Board of Advisors and Deputy Director. In 2017, Sarah became a Partner and Investment Manager at OneVentures, one of Australia's leading venture capital firms. In 2018, they became a Board Observer at Paragen Bio, a biotechnology company. In 2019, they joined Kira Biotech Pty Ltd as a Non Executive Director and Chair of the Board, Life Sciences Queensland Limited as a Nonexecutive Director, and Blade Therapeutics as a Board Observer. In 2020, Sarah became a Board Observer and Alternate Director at Vaxxas. Finally, in 2021, they joined Axial Therapeutics, Inc. as a Non Executive Director.

Sarah Meibusch completed their Bachelor of Agricultural Science at The University of Queensland in 1998, with a field of study in Biochemistry and Animal Science. Sarah then went on to pursue a Masters at Cornell University, which they completed in 2001, with a field of study in Commercialization of Innovation. In 2007, they attended Harvard Business School's Executive Education Program, specializing in Negotiation and Competitive Decision Making. Finally, in 2015, they graduated from the Australian Institute of Company Directors' Graduate of the Australian Company Directors Course (GAICD).